IBDEI0VA ; ; 09-AUG-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41091,1,3,0)
 ;;=3^Blindness-Rt Eye/Normal Vision-Lt Eye
 ;;^UTILITY(U,$J,358.3,41091,1,4,0)
 ;;=4^H54.41
 ;;^UTILITY(U,$J,358.3,41091,2)
 ;;=^5006363
 ;;^UTILITY(U,$J,358.3,41092,0)
 ;;=H54.42^^121^1765^6
 ;;^UTILITY(U,$J,358.3,41092,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41092,1,3,0)
 ;;=3^Blindness-Lt Eye/Normal Vision-Rt Eye
 ;;^UTILITY(U,$J,358.3,41092,1,4,0)
 ;;=4^H54.42
 ;;^UTILITY(U,$J,358.3,41092,2)
 ;;=^5133518
 ;;^UTILITY(U,$J,358.3,41093,0)
 ;;=H54.7^^121^1765^9
 ;;^UTILITY(U,$J,358.3,41093,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41093,1,3,0)
 ;;=3^Visual Loss
 ;;^UTILITY(U,$J,358.3,41093,1,4,0)
 ;;=4^H54.7
 ;;^UTILITY(U,$J,358.3,41093,2)
 ;;=^5006368
 ;;^UTILITY(U,$J,358.3,41094,0)
 ;;=H54.8^^121^1765^1
 ;;^UTILITY(U,$J,358.3,41094,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41094,1,3,0)
 ;;=3^Legal Blindness,as Defined in USA
 ;;^UTILITY(U,$J,358.3,41094,1,4,0)
 ;;=4^H54.8
 ;;^UTILITY(U,$J,358.3,41094,2)
 ;;=^5006369
 ;;^UTILITY(U,$J,358.3,41095,0)
 ;;=H54.40^^121^1765^7
 ;;^UTILITY(U,$J,358.3,41095,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41095,1,3,0)
 ;;=3^Monocular,Blindness in One Eye
 ;;^UTILITY(U,$J,358.3,41095,1,4,0)
 ;;=4^H54.40
 ;;^UTILITY(U,$J,358.3,41095,2)
 ;;=^5006362
 ;;^UTILITY(U,$J,358.3,41096,0)
 ;;=H53.8^^121^1765^11
 ;;^UTILITY(U,$J,358.3,41096,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41096,1,3,0)
 ;;=3^Visual Disturbances
 ;;^UTILITY(U,$J,358.3,41096,1,4,0)
 ;;=4^H53.8
 ;;^UTILITY(U,$J,358.3,41096,2)
 ;;=^5006356
 ;;^UTILITY(U,$J,358.3,41097,0)
 ;;=H53.71^^121^1765^12
 ;;^UTILITY(U,$J,358.3,41097,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41097,1,3,0)
 ;;=3^Glare Sensitivity
 ;;^UTILITY(U,$J,358.3,41097,1,4,0)
 ;;=4^H53.71
 ;;^UTILITY(U,$J,358.3,41097,2)
 ;;=^5006354
 ;;^UTILITY(U,$J,358.3,41098,0)
 ;;=H53.72^^121^1765^13
 ;;^UTILITY(U,$J,358.3,41098,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41098,1,3,0)
 ;;=3^Impaired Contrast Sensitivity
 ;;^UTILITY(U,$J,358.3,41098,1,4,0)
 ;;=4^H53.72
 ;;^UTILITY(U,$J,358.3,41098,2)
 ;;=^5006355
 ;;^UTILITY(U,$J,358.3,41099,0)
 ;;=H57.11^^121^1765^14
 ;;^UTILITY(U,$J,358.3,41099,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41099,1,3,0)
 ;;=3^Ocular Pain,Right Eye
 ;;^UTILITY(U,$J,358.3,41099,1,4,0)
 ;;=4^H57.11
 ;;^UTILITY(U,$J,358.3,41099,2)
 ;;=^5006382
 ;;^UTILITY(U,$J,358.3,41100,0)
 ;;=H57.12^^121^1765^15
 ;;^UTILITY(U,$J,358.3,41100,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41100,1,3,0)
 ;;=3^Ocular Pain,Left Eye
 ;;^UTILITY(U,$J,358.3,41100,1,4,0)
 ;;=4^H57.12
 ;;^UTILITY(U,$J,358.3,41100,2)
 ;;=^5006383
 ;;^UTILITY(U,$J,358.3,41101,0)
 ;;=H57.13^^121^1765^16
 ;;^UTILITY(U,$J,358.3,41101,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41101,1,3,0)
 ;;=3^Ocular Pain,Bilateral
 ;;^UTILITY(U,$J,358.3,41101,1,4,0)
 ;;=4^H57.13
 ;;^UTILITY(U,$J,358.3,41101,2)
 ;;=^5006384
 ;;^UTILITY(U,$J,358.3,41102,0)
 ;;=Z01.00^^121^1765^17
 ;;^UTILITY(U,$J,358.3,41102,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41102,1,3,0)
 ;;=3^Eye/Vision Exam w/o Abnormal Findings
 ;;^UTILITY(U,$J,358.3,41102,1,4,0)
 ;;=4^Z01.00
 ;;^UTILITY(U,$J,358.3,41102,2)
 ;;=^5062612
 ;;^UTILITY(U,$J,358.3,41103,0)
 ;;=Z01.01^^121^1765^18
 ;;^UTILITY(U,$J,358.3,41103,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41103,1,3,0)
 ;;=3^Eye/Vision Exam w/ Abnormal Findings
 ;;^UTILITY(U,$J,358.3,41103,1,4,0)
 ;;=4^Z01.01
 ;;^UTILITY(U,$J,358.3,41103,2)
 ;;=^5062613
 ;;^UTILITY(U,$J,358.3,41104,0)
 ;;=H57.9^^121^1765^19
 ;;^UTILITY(U,$J,358.3,41104,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41104,1,3,0)
 ;;=3^Eye and Adnexa Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,41104,1,4,0)
 ;;=4^H57.9
 ;;^UTILITY(U,$J,358.3,41104,2)
 ;;=^269333
 ;;^UTILITY(U,$J,358.3,41105,0)
 ;;=I10.^^121^1765^20
 ;;^UTILITY(U,$J,358.3,41105,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41105,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,41105,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,41105,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,41106,0)
 ;;=Z21.^^121^1765^21
 ;;^UTILITY(U,$J,358.3,41106,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41106,1,3,0)
 ;;=3^Asymptomatic HIV Infection Status
 ;;^UTILITY(U,$J,358.3,41106,1,4,0)
 ;;=4^Z21.
 ;;^UTILITY(U,$J,358.3,41106,2)
 ;;=^5062777
 ;;^UTILITY(U,$J,358.3,41107,0)
 ;;=E11.9^^121^1766^1
 ;;^UTILITY(U,$J,358.3,41107,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41107,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,41107,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,41107,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,41108,0)
 ;;=E11.39^^121^1766^2
 ;;^UTILITY(U,$J,358.3,41108,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41108,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complications
 ;;^UTILITY(U,$J,358.3,41108,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,41108,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,41109,0)
 ;;=E11.359^^121^1766^6
 ;;^UTILITY(U,$J,358.3,41109,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41109,1,3,0)
 ;;=3^DM Type 2 w/ Proliferative DR, no CME
 ;;^UTILITY(U,$J,358.3,41109,1,4,0)
 ;;=4^E11.359
 ;;^UTILITY(U,$J,358.3,41109,2)
 ;;=^5002641
 ;;^UTILITY(U,$J,358.3,41110,0)
 ;;=E11.351^^121^1766^11
 ;;^UTILITY(U,$J,358.3,41110,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41110,1,3,0)
 ;;=3^DM Type 2 w/ Proliferative DR w/ CME
 ;;^UTILITY(U,$J,358.3,41110,1,4,0)
 ;;=4^E11.351
 ;;^UTILITY(U,$J,358.3,41110,2)
 ;;=^5002640
 ;;^UTILITY(U,$J,358.3,41111,0)
 ;;=E11.349^^121^1766^5
 ;;^UTILITY(U,$J,358.3,41111,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41111,1,3,0)
 ;;=3^DM Type 2 w/ Non Prolif DR, Severe, no CME
 ;;^UTILITY(U,$J,358.3,41111,1,4,0)
 ;;=4^E11.349
 ;;^UTILITY(U,$J,358.3,41111,2)
 ;;=^5002639
 ;;^UTILITY(U,$J,358.3,41112,0)
 ;;=E11.341^^121^1766^10
 ;;^UTILITY(U,$J,358.3,41112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41112,1,3,0)
 ;;=3^DM Type 2 w/ Non Prolif DR, Severe, w/ CME
 ;;^UTILITY(U,$J,358.3,41112,1,4,0)
 ;;=4^E11.341
 ;;^UTILITY(U,$J,358.3,41112,2)
 ;;=^5002638
 ;;^UTILITY(U,$J,358.3,41113,0)
 ;;=E11.339^^121^1766^4
 ;;^UTILITY(U,$J,358.3,41113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41113,1,3,0)
 ;;=3^DM Type 2 w/ Non Prolif DR, Moderate, no CME
 ;;^UTILITY(U,$J,358.3,41113,1,4,0)
 ;;=4^E11.339
 ;;^UTILITY(U,$J,358.3,41113,2)
 ;;=^5002637
 ;;^UTILITY(U,$J,358.3,41114,0)
 ;;=E11.331^^121^1766^9
 ;;^UTILITY(U,$J,358.3,41114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41114,1,3,0)
 ;;=3^DM Type 2 w/ Non Prolif DR, Moderate, w/ CME
 ;;^UTILITY(U,$J,358.3,41114,1,4,0)
 ;;=4^E11.331
 ;;^UTILITY(U,$J,358.3,41114,2)
 ;;=^5002636
 ;;^UTILITY(U,$J,358.3,41115,0)
 ;;=E11.329^^121^1766^3
 ;;^UTILITY(U,$J,358.3,41115,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41115,1,3,0)
 ;;=3^DM Type 2 w/ NonProlif DR,Mild,No CME
 ;;^UTILITY(U,$J,358.3,41115,1,4,0)
 ;;=4^E11.329
 ;;^UTILITY(U,$J,358.3,41115,2)
 ;;=^5002635
 ;;^UTILITY(U,$J,358.3,41116,0)
 ;;=E11.321^^121^1766^8
 ;;^UTILITY(U,$J,358.3,41116,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41116,1,3,0)
 ;;=3^DM Type 2 w/ NonProlif DR,Mild,w/ CME
 ;;^UTILITY(U,$J,358.3,41116,1,4,0)
 ;;=4^E11.321
 ;;^UTILITY(U,$J,358.3,41116,2)
 ;;=^5002634
 ;;^UTILITY(U,$J,358.3,41117,0)
 ;;=E10.9^^121^1766^32
 ;;^UTILITY(U,$J,358.3,41117,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41117,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,41117,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,41117,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,41118,0)
 ;;=E10.39^^121^1766^33
 ;;^UTILITY(U,$J,358.3,41118,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41118,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Ophthalmic Complication
 ;;^UTILITY(U,$J,358.3,41118,1,4,0)
 ;;=4^E10.39
 ;;^UTILITY(U,$J,358.3,41118,2)
 ;;=^5002603
 ;;^UTILITY(U,$J,358.3,41119,0)
 ;;=E10.329^^121^1766^34
 ;;^UTILITY(U,$J,358.3,41119,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41119,1,3,0)
 ;;=3^DM Type 1 w/ Mild Nonprolif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,41119,1,4,0)
 ;;=4^E10.329
 ;;^UTILITY(U,$J,358.3,41119,2)
 ;;=^5002595
 ;;^UTILITY(U,$J,358.3,41120,0)
 ;;=E10.339^^121^1766^35
 ;;^UTILITY(U,$J,358.3,41120,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41120,1,3,0)
 ;;=3^DM Type 1 w/ Moderate Nonprolif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,41120,1,4,0)
 ;;=4^E10.339
 ;;^UTILITY(U,$J,358.3,41120,2)
 ;;=^5002597
 ;;^UTILITY(U,$J,358.3,41121,0)
 ;;=E10.349^^121^1766^36
 ;;^UTILITY(U,$J,358.3,41121,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41121,1,3,0)
 ;;=3^DM Type 1 w/ Severe Nonprolif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,41121,1,4,0)
 ;;=4^E10.349
 ;;^UTILITY(U,$J,358.3,41121,2)
 ;;=^5002599
 ;;^UTILITY(U,$J,358.3,41122,0)
 ;;=E10.359^^121^1766^37
 ;;^UTILITY(U,$J,358.3,41122,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41122,1,3,0)
 ;;=3^DM Type 1 w/ Prolif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,41122,1,4,0)
 ;;=4^E10.359
 ;;^UTILITY(U,$J,358.3,41122,2)
 ;;=^5002601
 ;;^UTILITY(U,$J,358.3,41123,0)
 ;;=H35.81^^121^1766^7
 ;;^UTILITY(U,$J,358.3,41123,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41123,1,3,0)
 ;;=3^Retinal Edema/CME Other Etiology
 ;;^UTILITY(U,$J,358.3,41123,1,4,0)
 ;;=4^H35.81
 ;;^UTILITY(U,$J,358.3,41123,2)
 ;;=^5005715
 ;;^UTILITY(U,$J,358.3,41124,0)
 ;;=H34.11^^121^1766^12
 ;;^UTILITY(U,$J,358.3,41124,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41124,1,3,0)
 ;;=3^Central Retinal Artery Occlusion,Right Eye
 ;;^UTILITY(U,$J,358.3,41124,1,4,0)
 ;;=4^H34.11
 ;;^UTILITY(U,$J,358.3,41124,2)
 ;;=^5005557
 ;;^UTILITY(U,$J,358.3,41125,0)
 ;;=H34.12^^121^1766^13
 ;;^UTILITY(U,$J,358.3,41125,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41125,1,3,0)
 ;;=3^Central Retinal Artery Occlusion,Left Eye
 ;;^UTILITY(U,$J,358.3,41125,1,4,0)
 ;;=4^H34.12
 ;;^UTILITY(U,$J,358.3,41125,2)
 ;;=^5005558
 ;;^UTILITY(U,$J,358.3,41126,0)
 ;;=H34.231^^121^1766^14
 ;;^UTILITY(U,$J,358.3,41126,1,0)
 ;;=^358.31IA^4^2
